Mecasermin
Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C331H512N94O101S7 |
Molar mass | 7648.67 g/mol g·mol−1 |
(what is this?) (verify) |
Mecasermin (INN) (trade name Increlex) is recombinant human insulin-like growth factor 1 (IGF-I), which is used for the long-term treatment of growth failure in children with severe primary IGF-I deficiency.[1][2]
This drug is not to be confused with mecasermin rinfabate (trade name Iplex), which is a combination of recombinant human IGF-1 (rhIGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 serves to prolong the action of IGF-1 in the human body.
References
- ^ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management. 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186. PMID 19707272.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ "Increlex". Drugs.com. Retrieved 10 January 2010.